Insulinotropic peptide derivatives
CA 2446394 C · Owner: Wu, Dengxi · Inventors: Yu, Gang; Zhao, Shaoling; Zhu, Zhiyong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to derivates of an insulinotropic peptide Exendin-4 and , pharmaceutically acceptable salts produced thereof which are useful for the , treatment of type II diabetes. Exendin-4 has the chemical structure as shown below: His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-X-Glu-Glu-Glu-Ala-Val-Y- Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Z In which:, X represents Arg, Leu or Ile Y represents His, Arg or Lys and Z represents Arg-OH, -OH, -NH2 or Lys-OH. The derivates of this invention may be prepared by synthetic chemical means and more , easily, by the recombinant techniques which makes it possible to commercial production.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 8, 2002 and granted August 16, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 8, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 8, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.